TrovaGene said this week that it has obtained an exclusive worldwide license for mutations of the SF3B1 splicing factor that are associated with disease progression and chemotherapy response in chronic lymphocytic leukemia.
"Research results suggest that SF3B1 mutations represent important incremental diagnostic markers beyond TP53 disruptions and NOTCH1 mutations in CLL patients, and may also provide a therapeutic target for SF3B1 inhibitors, which are currently in pre-clinical development," TrovaGene said in a statement.